Use of Natural Compounds as a potential therapeutic agent against COVID-19

2021 ◽  
Vol 26 ◽  
Author(s):  
Shadma Wahab ◽  
Irfan Ahmad ◽  
Safia Irfan ◽  
Mohammad Hassan Baig ◽  
Abd-ElAziem Farouk ◽  
...  
Keyword(s):  
Natural Products ◽  
Severe Acute Respiratory Syndrome ◽  
Drug Development ◽  
Respiratory System ◽  
Crucial Role ◽  
Therapeutic Agent ◽  
Natural Compounds ◽  
Current Status ◽  
Effective Vaccine ◽  
Novel Coronavirus

: The current 2019-nCoV outbreak is becoming extremely noxious and has affected the whole world. Its control is challenging because there is no effective vaccine or drug available for Coronavirus disease. The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), previously named as 2019 novel Coronavirus (2019-nCoV), primarily targets the human respiratory system to lung lesions and lethal pneumonia. Natural products have always shown a crucial role in the process of drug development against various diseases. They could be leads for further drug development to combat emergent mutants of the coronavirus. In this review, the current status of natural compounds and their derivatives acting against different species of CoV are discussed.

scholarly journals Current Status of Computed Tomography in Novel Coronavirus Disease 2019 Pneumonia

2020 ◽  
Vol 56 (02) ◽  
pp. 062-066
Author(s):  
Kumble Seetharama Madhusudhan ◽  
Deep Narayan Srivastava
Keyword(s):  
Computed Tomography ◽  
Polymerase Chain Reaction ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory System ◽  
Current Status ◽  
Imaging Features ◽  
The Novel ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Novel Coronavirus

AbstarctThe novel coronavirus disease, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), has developed into a pandemic affecting more than three million people worldwide. It predominantly affects the respiratory system and patients present with fever, dry cough, dyspnea, and myalgia. The confirmatory diagnostic test is real-time reverse transcriptase polymerase chain reaction on blood or respiratory samples. Imaging with computed tomography, although not routinely recommended, may not only assist in making a diagnosis but also in assessing disease progression, assessing complications, and in prognostication. This review describes the objectives, techniques, imaging features, and reporting of computed tomography findings of SARS-CoV2 pneumonia.

Novel Coronavirus Disease (COVID-19): A Narrative Review Based on Current Status

2020 ◽  
Vol 18 ◽  
Author(s):  
Rina Das ◽  
Dinesh Kumar Mehta ◽  
Meenakshi Dhanawat
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Clinical Symptoms ◽  
Virus Disease ◽  
Relevant Literature ◽  
World Health ◽  
Current Status ◽  
Future Research ◽  
Treatment And Prevention ◽  
First Case ◽  
Novel Coronavirus

Abstract:: A novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared and expanded globally by the end of year in 2019 from Wuhan, China, causing severe acute respiratory syndrome. During its initial stage, the disease was called the novel coronavirus (2019-nCoV). It was named COVID-19 by the World Health Organization (WHO) on 11 February 2020. The WHO declared worldwide the SARS-CoV-2 virus a pandemic on March 2020. On 30 January 2020 the first case of Corona Virus Disease 2019 (COVID-19) was reported in India. Now in current situation the virus is floating in almost every part of the province and rest of the globe. -: On the basis of novel published evidences, we efficiently summarized the reported work with reference to COVID-19 epidemiology, pathogen, clinical symptoms, treatment and prevention. Using several worldwide electronic scientific databases such as Pubmed, Medline, Embase, Science direct, Scopus, etc were utilized for extensive investigation of relevant literature. -: This review is written in the hope of encouraging the people successfully with the key learning points from the underway efforts to perceive and manage SARS-CoV-2, suggesting sailent points for expanding future research.

scholarly journals Does Concurrent Existence of Asthma or COPD Affect Susceptibility & Outcomes to Novel Coronavirus Infections?

The Physician ◽  
2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Akash Srinivasan ◽  
Indranil Chakravorty ◽  
Koottalai Srinivasan
Keyword(s):  
Respiratory Failure ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory System ◽  
Chronic Lung Disease ◽  
Lung Diseases ◽  
Healthcare Professionals ◽  
Chronic Lung Diseases ◽  
The World ◽  
Mobile Population ◽  
Novel Coronavirus

The SARS-CoV-2 virus causing COVID-19 pandemic across the world has highlighted the risk of human-to-human transmission, the speed of spread in a globally mobile population and the need for health services to be flexible in their responses to hitherto unknown challenges. One of the hallmarks of COVID-19 is severe acute respiratory syndrome presenting with widespread viral pneumonitis and respiratory failure. It is therefore not unusual for patients with chronic lung diseases such as asthma, COPD, and bronchiectasis to be concerned regarding their particular vulnerability. As healthcare professionals responsible for the care of such patients, it is important to understand how the SARS-CoV-2 virus impacts the respiratory system and the outcomes for patients with chronic lung disease. This review examines the evidence and offers sensible guidance until more is known.

scholarly journals Structure-Based Virtual Screening of a Natural Product Database to Identify Several Possible SARS-CoV-2 Main Protease Inhibitors

2020 ◽  
Author(s):  
Azhagiya Singam Ettayapuram Ramaprasad ◽  
Michele La merrill ◽  
Kathleen A. Durkin ◽  
Martyn T. Smith
Keyword(s):  
Natural Products ◽  
Natural Product ◽  
Respiratory Illness ◽  
Dynamics Simulation ◽  
Effective Vaccine ◽  
Main Protease ◽  
Novel Coronavirus ◽  
Seriously Ill Patients ◽  
Enormous Number ◽  
Seriously Ill

<p>A novel coronavirus (SARS-CoV-2) has been the cause of a recent pandemic of respiratory illness known as COVID-19. The lack of anti-viral drugs or vaccines to control the infection has resulted in an enormous number of seriously ill patients requiring hospitalization. In the absence of an effective vaccine, there is an urgent need for therapies which can fight COVID-19 infection. Readily available compounds in foods and plants may be one source of anti-viral compounds. Here, natural product chemicals from the Nuclei of Bioassays, Ecophysiology and Biosynthesis of Natural Products Database (NuBBE<sub>DB</sub>) were screened against the main protease (Mpro) of SARS-CoV-2. This protease was chosen as a target due to its importance in the replication of SARS-CoV-2. Molecular docking was used to screen the natural products against Mpro to identify potential candidates. The identified candidates were further filtered using molecular dynamics simulation investigation. Nine natural compounds were identified for experimental validation, with carlinoside and quercetin 3-o-sophoroside being the top candidates. </p>

Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective

2020 ◽  
Vol 20 ◽  
Author(s):  
Maryam Darvish ◽  
Mahshid Shahverdi
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Genome Structure ◽  
Viral Disease ◽  
Antiviral Drugs ◽  
Central China ◽  
Current Status ◽  
Future Perspective ◽  
Plasma Therapy ◽  
Therapeutic Measures ◽  
Novel Coronavirus

: The coronavirus disease 19 (COVID-19) is a highly pathogenic and transmissible viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in the city of Wuhan, Hubei Province, Central China and spread quickly around the world. The genome sequence of SARS-CoV-2 is phylogenetically related to batderived severe acute respiratory syndrome-like (SARS-like) coronaviruses, therefore bats could be the possible primary reservoirs. At present, there are no clinically approved vaccines or specific antiviral drugs for COVID-19. However, several broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical studies and resulted in the improvement of patients. In this regard, other therapies such as antiviral drugs, antibodies, stem cells and plasma therapy are being studied. In the current study, we reviewed the emergence, pathogenicity and the genome structure of COVID-19 infection. The main focus of this study is on the therapeutic approaches that may be effective against SARS-CoV-2.

New Viral Infection COVID-19: Current Status, Challenges and Possible Treatments

2020 ◽  
Vol 18 ◽  
Author(s):  
Vipan Kumar ◽  
Amruta Suryan ◽  
Jyoti Singh ◽  
Sandeep Kumar ◽  
Pradeep Kamboj ◽  
...  
Keyword(s):  
Treatment Options ◽  
Antiviral Agents ◽  
Viral Envelope ◽  
Current Status ◽  
Effective Vaccine ◽  
Plasma Therapy ◽  
Immunomodulatory Agents ◽  
Global Pandemic ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Since December 2019, the prevalence of novel coronavirus infection (named as COVID-19 by WHO on Feb 11, 2020) has become a growing healthcare concern worldwide. On March 11, 2020, the WHO declared COVID-19 a global pandemic. As no specific approved treatment options are available for the COVID-19 infection, several existing antiviral drugs in combination with others have become mainstay therapy. The targets for the treatment of the infection include viral targets such as polymerases, spike glycoproteins, membrane proteins, and viral envelope and host targets such as host proteases and host receptors. Antiviral agents, immunomodulatory agents, and empiric broad-spectrum antibiotics can be used as treatment therapies for the infection. Convalescent plasma therapy has also been proposed as an effective treatment for COVID-19. Additionally, many studies are ongoing to develop a potent and effective vaccine that completely blocks SARS-CoV-2. Nevertheless, prevention of spreading of the virus remains the first and foremost step towards controlling and managing the coronavirus infection.

scholarly journals The Potential Use of Electromagnetic Radiation to Combat Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Particles: A Numerical Analysis

2021 ◽  
Author(s):  
Haider Raad ◽  
Colin Terry
Keyword(s):  
Numerical Analysis ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory System ◽  
Electromagnetic Waves ◽  
Maximum Energy ◽  
The Novel ◽  
Virus Particles ◽  
Novel Coronavirus ◽  
The Waves ◽  
Potential Use

The novel coronavirus disease 2019 (COVID-19) has shown the danger that can be caused by small, airborne and contagious virus particles such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To prevent the mass spreading of such viruses, the use of electromagnetic waves could be used to combat the spreading of the virus. Particularly, the waves could force any virus particles to oscillate in resonance with the frequency of the wave and destroy themselves before the virus would enter the respiratory system. This paper describes the use of numerical simulations to analyze the effects of exposing a SARS-CoV-2 particle to electromagnetic waves at a range of frequencies and to determine which frequencies have the potential of causing resonance within the virus which would yield to the maximum energy absorption. Such technique could be utilized in preventive/protective devices and disinfection equipment.

scholarly journals Therapeutic Strategies of COVID-19: from Natural Compounds to Vaccine Trials

2020 ◽  
Vol 11 (1) ◽  
pp. 8318-8373
Keyword(s):  
Monoclonal Antibodies ◽  
Immune System ◽  
Severe Acute Respiratory Syndrome ◽  
Natural Compounds ◽  
Therapeutic Strategies ◽  
Plasma Therapy ◽  
Global Epidemic ◽  
Vaccine Trials ◽  
The World ◽  
Novel Coronavirus

Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is a novel coronavirus that caused a global epidemic named COVID-19. This disease continues to kill thousands of people around the world. Physiopathological studies showed that different organs such as lungs, brain, kidneys, immune system, and heart are affected directly and/or indirectly by this disease. With the absence of a vaccine, several treatments have been proposed, including old antiviral drugs, synthetic pharmacophores, and natural antiviral bioactive compounds. These molecules presented promising results with specific action on the virus. Moreover, other strategies are underway, such as the use of monoclonal antibodies, cell therapy, plasma therapy, and vaccine trials. In this work, we highlight the therapeutic strategies of COVID-19 natural compounds to vaccine trials.

scholarly journals Structure-Based Virtual Screening of a Natural Product Database to Identify Several Possible SARS-CoV-2 Main Protease Inhibitors

2020 ◽  
Author(s):  
Azhagiya Singam Ettayapuram Ramaprasad ◽  
Michele La merrill ◽  
Kathleen A. Durkin ◽  
Martyn T. Smith
Keyword(s):  
Natural Products ◽  
Natural Product ◽  
Respiratory Illness ◽  
Dynamics Simulation ◽  
Effective Vaccine ◽  
Main Protease ◽  
Novel Coronavirus ◽  
Seriously Ill Patients ◽  
Enormous Number ◽  
Seriously Ill

<p>A novel coronavirus (SARS-CoV-2) has been the cause of a recent pandemic of respiratory illness known as COVID-19. The lack of anti-viral drugs or vaccines to control the infection has resulted in an enormous number of seriously ill patients requiring hospitalization. In the absence of an effective vaccine, there is an urgent need for therapies which can fight COVID-19 infection. Readily available compounds in foods and plants may be one source of anti-viral compounds. Here, natural product chemicals from the Nuclei of Bioassays, Ecophysiology and Biosynthesis of Natural Products Database (NuBBE<sub>DB</sub>) were screened against the main protease (Mpro) of SARS-CoV-2. This protease was chosen as a target due to its importance in the replication of SARS-CoV-2. Molecular docking was used to screen the natural products against Mpro to identify potential candidates. The identified candidates were further filtered using molecular dynamics simulation investigation. Nine natural compounds were identified for experimental validation, with carlinoside and quercetin 3-o-sophoroside being the top candidates. </p>

scholarly journals Structural and Drug Screening Analysis of the Non-structural Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Virus Extracted From Indian Coronavirus Disease 2019 Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Nupur Biswas ◽  
Krishna Kumar ◽  
Priyanka Mallick ◽  
Subhrangshu Das ◽  
Izaz Monir Kamal ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Drug Screening ◽  
Structural Information ◽  
Protein Complexes ◽  
Three Dimensional ◽  
Host Protein ◽  
Structural Proteins ◽  
Effective Vaccine ◽  
Indian Patients ◽  
Novel Coronavirus

The novel coronavirus 2 (nCoV2) outbreaks took place in December 2019 in Wuhan City, Hubei Province, China. It continued to spread worldwide in an unprecedented manner, bringing the whole world to a lockdown and causing severe loss of life and economic stability. The coronavirus disease 2019 (COVID-19) pandemic has also affected India, infecting more than 10 million till 31st December 2020 and resulting in more than a hundred thousand deaths. In the absence of an effective vaccine, it is imperative to understand the phenotypic outcome of the genetic variants and subsequently the mode of action of its proteins with respect to human proteins and other bio-molecules. Availability of a large number of genomic and mutational data extracted from the nCoV2 virus infecting Indian patients in a public repository provided an opportunity to understand and analyze the specific variations of the virus in India and their impact in broader perspectives. Non-structural proteins (NSPs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) virus play a major role in its survival as well as virulence power. Here, we provide a detailed overview of the SARS-CoV2 NSPs including primary and secondary structural information, mutational frequency of the Indian and Wuhan variants, phylogenetic profiles, three-dimensional (3D) structural perspectives using homology modeling and molecular dynamics analyses for wild-type and selected variants, host-interactome analysis and viral–host protein complexes, and in silico drug screening with known antivirals and other drugs against the SARS-CoV2 NSPs isolated from the variants found within Indian patients across various regions of the country. All this information is categorized in the form of a database named, Database of NSPs of India specific Novel Coronavirus (DbNSP InC), which is freely available at http://www.hpppi.iicb.res.in/covid19/index.php.

Sign in / Sign up

Export Citation Format

Share Document